Document Detail

Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis.
MedLine Citation:
PMID:  9810957     Owner:  NLM     Status:  MEDLINE    
Twenty two patients with multiple sclerosis, complaining of frequency of day time micturition, completed a double blind crossover trial of desmopressin (DDAVP nasal spray) versus placebo. There was a significant decrease in micturition frequency in the 6 hour post-treatment period from 3.1 voids after placebo to 2.4 voids and a significant reduction in urinary volume after desmopressin. Eighty per cent of patients preferred the active treatment phase. Mean 24 hour urinary volume did not differ between active and placebo treatments and patients did not complain of increased night time frequency. Transient symptoms of hyponatraemia occurred in one patient but these resolved within 48 hours of stopping desmopressin. There were otherwise no side effects and mean serum sodium concentrations of the group remained unchanged throughout the study. The clinical indications for prescribing daytime desmopressin are discussed and the importance of patient compliance stressed.
P A Hoverd; C J Fowler
Related Documents :
18850287 - Diversity of birds at panipat refinery, haryana (india).
18601757 - Intravesical anesthesia for bladder tissue biopsies. comparison of two methods.
11268307 - The application of appendiceal mitrofanoff principle to stanford pouch.
11482747 - Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine.
603217 - Intensive physical therapy after fractures of the femoral shaft.
23816417 - A meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  65     ISSN:  0022-3050     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  1998 Nov 
Date Detail:
Created Date:  1998-12-10     Completed Date:  1998-12-10     Revised Date:  2008-11-20    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  778-80     Citation Subset:  IM    
Department of Uro-Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cross-Over Studies
Deamino Arginine Vasopressin / therapeutic use*
Double-Blind Method
Middle Aged
Multiple Sclerosis / complications*
Patient Compliance
Renal Agents / therapeutic use*
Sodium / blood
Treatment Outcome
Urination Disorders / drug therapy*
Reg. No./Substance:
0/Renal Agents; 16679-58-6/Deamino Arginine Vasopressin; 7440-23-5/Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.
Next Document:  Genetic and environmental risk factors for Parkinson's disease in a Chinese population.